Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Maraviroc is the first antiretroviral (ART) drug to target a human protein, the CCR5 coreceptor; however, the mechanisms of maraviroc-associated immunomodulation in human immunodeficiency virus (HIV)-infected subjects remain to be elucidated. Regulatory T cells (Tregs) play a key role in HIV-associated immunopathology and are susceptible to maraviroc-mediated CCR5 blockade. Our aim was to evaluate the effect of maraviroc on Tregs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Infect Dis

Title: The Journal of infectious diseases

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1537-6613

ISSN (Print): 0022-1899

Publication date (Electronic): Sep 15 2014

Volume: 210

Issue: 6

Affiliations

[1 ] Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville.

[2 ] Laboratory of Molecular Immunobiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.

[3 ] Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville Department of Medical Microbiology and Immunology, University of California, Davis.

[4 ] Infectious Diseases and HIV/AIDS Unit, Department of Internal Medicine, Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, IISPV, Spain.

Article

Publisher Item ID: jiu180

DOI: 10.1093/infdis/jiu180

PubMed ID: 24652492

SO-VID: 2c879f88-9228-46ce-b4c2-0f40f6b2cb3c

Copyright © © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.